Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2014

Open Access 01-06-2014 | Review

How to build an inducible cartilage-specific transgenic mouse

Authors: Esmeralda N Blaney Davidson, Fons AJ van de Loo, Wim B van den Berg, Peter M van der Kraan

Published in: Arthritis Research & Therapy | Issue 3/2014

Login to get access

Abstract

Transgenic mice are used to study the roles of specific proteins in an intact living system. Use of transgenic mice to study processes in cartilage, however, poses some challenges. First of all, many factors involved in cartilage homeostasis and disease are also crucial factors in embryogenesis. Therefore, meddling with these factors often leads to death before birth, and mice who do survive cannot be considered normal. The build-up of cartilage in these mice is altered, making it nearly impossible to truly interpret the role of a protein in adult cartilage function. An elegant way to overcome these limitations is to make transgenic mice time- and tissue-specific, thereby omitting side-effects in tissues other than cartilage and during embryology. This review discusses the potential building blocks for making an inducible cartilage-specific transgenic mouse. We review which promoters can be used to gain chondrocyte-specificity - all chondrocytes or a specific subset thereof - as well as different systems that can be used to enable inducibility of a transgene.
Literature
1.
Cheah KS, Lau ET, Au PK, Tam PP: Expression of the mouse alpha 1(II) collagen gene is not restricted to cartilage during development. Development. 1991, 111: 945-953.PubMed
2.
Zhou G, Garofalo S, Mukhopadhyay K, Lefebvre V, Smith CN, Eberspaecher H, de Crombrugghe B: A 182 bp fragment of the mouse pro alpha 1(II) collagen gene is sufficient to direct chondrocyte expression in transgenic mice. J Cell Sci. 1995, 108: 3677-3684.PubMed
3.
Leung KK, Ng LJ, Ho KK, Tam PP, Cheah KS: Different cis-regulatory DNA elements mediate developmental stage- and tissue-specific expression of the human COL2A1 gene in transgenic mice. J Cell Biol. 1998, 141: 1291-1300.PubMedCentralCrossRefPubMed
4.
Mukhopadhyay K, Lefebvre V, Zhou G, Garofalo S, Kimura JH, de Crombrugghe B: Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene. J Biol Chem. 1995, 270: 27711-27719.CrossRefPubMed
5.
Lefebvre V, Zhou G, Mukhopadhyay K, Smith CN, Zhang Z, Eberspaecher H, Zhou X, Sinha S, Maity SN, de Crombrugghe B: An 18-base-pair sequence in the mouse proalpha1(II) collagen gene is sufficient for expression in cartilage and binds nuclear proteins that are selectively expressed in chondrocytes. Mol Cell Biol. 1996, 16: 4512-4523.PubMedCentralPubMed
6.
Oh CD, Maity SN, Lu JF, Zhang J, Liang S, Coustry F, de Crombrugghe B, Yasuda H: Identification of SOX9 interaction sites in the genome of chondrocytes. PLoS One. 2010, 5: e10113-PubMedCentralCrossRefPubMed
7.
Ovchinnikov DA, Deng JM, Ogunrinu G, Behringer RR: Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. Genesis. 2000, 26: 145-146.CrossRefPubMed
8.
Sakai K, Hiripi L, Glumoff V, Brandau O, Eerola R, Vuorio E, Bosze Z, Fassler R, Aszodi A: Stage- and tissue-specific expression of a Col2a1-Cre fusion gene in transgenic mice. Matrix Biol. 2001, 19: 761-767.CrossRefPubMed
9.
Belteki G, Haigh J, Kabacs N, Haigh K, Sison K, Costantini F, Whitsett J, Quaggin SE, Nagy A: Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res. 2005, 33: e51-PubMedCentralCrossRefPubMed
10.
Sugimoto M, Kimura T, Tsumaki N, Matsui Y, Nakata K, Kawahata H, Yasui N, Kitamura Y, Nomura S, Ochi T: Differential in situ expression of alpha2(XI) collagen mRNA isoforms in the developing mouse. Cell Tissue Res. 1998, 292: 325-332.CrossRefPubMed
11.
Tsumaki N, Kimura T, Matsui Y, Nakata K, Ochi T: Separable cis-regulatory elements that contribute to tissue- and site-specific alpha 2(XI) collagen gene expression in the embryonic mouse cartilage. J Cell Biol. 1996, 134: 1573-1582.CrossRefPubMed
12.
Tsumaki N, Sugimoto M, Nakata K, Matsui Y, Ochi T, Kimura T: Separable regulatory elements from pro-alpha 2 (XI) collagen gene drive distinct patterns of cartilage-specific expression in transgenic mice. Ann N Y Acad Sci. 1996, 785: 340-342.CrossRefPubMed
13.
Krebsbach PH, Nakata K, Bernier SM, Hatano O, Miyashita T, Rhodes CS, Yamada Y: Identification of a minimum enhancer sequence for the type II collagen gene reveals several core sequence motifs in common with the link protein gene. J Biol Chem. 1996, 271: 4298-4303.CrossRefPubMed
14.
Liu Y, Li H, Tanaka K, Tsumaki N, Yamada Y: Identification of an enhancer sequence within the first intron required for cartilage-specific transcription of the alpha2(XI) collagen gene. J Biol Chem. 2000, 275: 12712-12718.CrossRefPubMed
15.
Li SW, Arita M, Kopen GC, Phinney DG, Prockop DJ: A 1,064 bp fragment from the promoter region of the Col11a2 gene drives lacZ expression not only in cartilage but also in osteoblasts adjacent to regions undergoing both endochondral and intramembranous ossification in mouse embryos. Matrix Biol. 1998, 17: 213-221.CrossRefPubMed
16.
Tsumaki N, Kimura T, Tanaka K, Kimura JH, Ochi T, Yamada Y: Modular arrangement of cartilage- and neural tissue-specific cis-elements in the mouse alpha2(XI) collagen promoter. J Biol Chem. 1998, 273: 22861-22864.CrossRefPubMed
17.
Fujimaki R, Hayashi K, Watanabe N, Yamada T, Toyama Y, Tezuka K, Hozumi N: Expression of Cre recombinase in the mouse developing chondrocytes driven by the mouse alpha2(XI) collagen promoter. J Bone Miner Metab. 2005, 23: 270-273.CrossRefPubMed
18.
Bridgewater LC, Lefebvre V, de Crombrugghe B: Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer. J Biol Chem. 1998, 273: 14998-15006.CrossRefPubMed
19.
Zhou G, Lefebvre V, Zhang Z, Eberspaecher H, de Crombrugghe B: Three high mobility group-like sequences within a 48-base pair enhancer of the Col2a1 gene are required for cartilage-specific expression in vivo. J Biol Chem. 1998, 273: 14989-14997.CrossRefPubMed
20.
Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B: SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol. 1997, 17: 2336-2346.PubMedCentralPubMed
21.
Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya K, Nifuji A, Noda M: SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem. 2000, 275: 10738-10744.CrossRefPubMed
22.
Doege K, Hall LB, McKinnon W, Chen L, Stephens DT, Garrison K: A remote upstream element regulates tissue-specific expression of the rat aggrecan gene. J Biol Chem. 2002, 277: 13989-13997.CrossRefPubMed
23.
Han Y, Lefebvre V: L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by securing binding of Sox9 to a far-upstream enhancer. Mol Cell Biol. 2008, 28: 4999-5013.PubMedCentralCrossRefPubMed
24.
Henry SP, Jang CW, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B: Generation of aggrecan-CreERT2 knockin mice for inducible Cre activity in adult cartilage. Genesis. 2009, 47: 805-814.PubMedCentralPubMed
25.
Klatt AR, Paulsson M, Wagener R: Expression of matrilins during maturation of mouse skeletal tissues. Matrix Biol. 2002, 21: 289-296.CrossRefPubMed
26.
Piecha D, Muratoglu S, Morgelin M, Hauser N, Studer D, Kiss I, Paulsson M, Deak F: Matrilin-2, a large, oligomeric matrix protein, is expressed by a great variety of cells and forms fibrillar networks. J Biol Chem. 1999, 274: 13353-13361.CrossRefPubMed
27.
Klatt AR, Nitsche DP, Kobbe B, Macht M, Paulsson M, Wagener R: Molecular structure, processing, and tissue distribution of matrilin-4. J Biol Chem. 2001, 276: 17267-17275.CrossRefPubMed
28.
Hauser N, Paulsson M, Heinegard D, Morgelin M: Interaction of cartilage matrix protein with aggrecan. Increased covalent cross-linking with tissue maturation. J Biol Chem. 1996, 271: 32247-32252.CrossRefPubMed
29.
Winterbottom N, Tondravi MM, Harrington TL, Klier FG, Vertel BM, Goetinck PF: Cartilage matrix protein is a component of the collagen fibril of cartilage. Dev Dyn. 1992, 193: 266-276.CrossRefPubMed
30.
Karcagi I, Rauch T, Hiripi L, Rentsendorj O, Nagy A, Bosze Z, Kiss I: Functional analysis of the regulatory regions of the matrilin-1 gene in transgenic mice reveals modular arrangement of tissue-specific control elements. Matrix Biol. 2004, 22: 605-618.CrossRefPubMed
31.
Rentsendorj O, Nagy A, Sinko I, Daraba A, Barta E, Kiss I: Highly conserved proximal promoter element harbouring paired Sox9-binding sites contributes to the tissue- and developmental stage-specific activity of the matrilin-1 gene. Biochem J. 2005, 389: 705-716.PubMedCentralCrossRefPubMed
32.
Jacenko O, Roberts DW, Campbell MR, McManus PM, Gress CJ, Tao Z: Linking hematopoiesis to endochondral skeletogenesis through analysis of mice transgenic for collagen X. Am J Pathol. 2002, 160: 2019-2034.PubMedCentralCrossRefPubMed
33.
Campbell MR, Gress CJ, Appleman EH, Jacenko O: Chicken collagen X regulatory sequences restrict transgene expression to hypertrophic cartilage in mice. Am J Pathol. 2004, 164: 487-499.PubMedCentralCrossRefPubMed
34.
Gebhard S, Poschl E, Riemer S, Bauer E, Hattori T, Eberspaecher H, Zhang Z, Lefebvre V, de Crombrugghe B, von der Mark K: A highly conserved enhancer in mammalian type X collagen genes drives high levels of tissue-specific expression in hypertrophic cartilage in vitro and in vivo. Matrix Biol. 2004, 23: 309-322.CrossRefPubMed
35.
Gebhard S, Hattori T, Bauer E, Bosl MR, Schlund B, Poschl E, Adam N, de Crombrugghe B, von der Mark K: BAC constructs in transgenic reporter mouse lines control efficient and specific LacZ expression in hypertrophic chondrocytes under the complete Col10a1 promoter. Histochem Cell Biol. 2007, 127: 183-194.PubMedCentralCrossRefPubMed
36.
Gebhard S, Hattori T, Bauer E, Schlund B, Bosl MR, de Crombrugghe B, von der Mark K: Specific expression of Cre recombinase in hypertrophic cartilage under the control of a BAC-Col10a1 promoter. Matrix Biol. 2008, 27: 693-699.PubMedCentralCrossRefPubMed
37.
Yang G, Cui F, Hou N, Cheng X, Zhang J, Wang Y, Jiang N, Gao X, Yang X: Transgenic mice that express Cre recombinase in hypertrophic chondrocytes. Genesis. 2005, 42: 33-36.CrossRefPubMed
38.
Zheng Q, Zhou G, Morello R, Chen Y, Garcia-Rojas X, Lee B: Type X collagen gene regulation by Runx2 contributes directly to its hypertrophic chondrocyte-specific expression in vivo. J Cell Biol. 2003, 162: 833-842.PubMedCentralCrossRefPubMed
39.
Li F, Lu Y, Ding M, Napierala D, Abbassi S, Chen Y, Duan X, Wang S, Lee B, Zheng Q: Runx2 contributes to murine Col10a1 gene regulation through direct interaction with its cis-enhancer. J Bone Miner Res. 2011, 26: 2899-2910.PubMedCentralCrossRefPubMed
40.
Dy P, Wang W, Bhattaram P, Wang Q, Wang L, Ballock RT, Lefebvre V: Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes. Dev Cell. 2012, 22: 597-609.PubMedCentralCrossRefPubMed
41.
Poole CA, Ayad S, Gilbert RT: Chondrons from articular cartilage. V. Immunohistochemical evaluation of type VI collagen organisation in isolated chondrons by light, confocal and electron microscopy. J Cell Sci. 1992, 103: 1101-1110.PubMed
42.
Braghetta P, Fabbro C, Piccolo S, Marvulli D, Bonaldo P, Volpin D, Bressan GM: Distinct regions control transcriptional activation of the alpha1(VI) collagen promoter in different tissues of transgenic mice. J Cell Biol. 1996, 135: 1163-1177.CrossRefPubMed
43.
Braghetta P, Vitale P, Piccolo S, Bonaldo P, Fabbro C, Girotto D, Volpin D, Bressan GM: Tissue-specific expression of promoter regions of the alpha1(VI) collagen gene in cell cultures and transgenic mice. Eur J Biochem. 1997, 247: 200-208.CrossRefPubMed
44.
Rountree RB, Schoor M, Chen H, Marks ME, Harley V, Mishina Y, Kingsley DM: BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol. 2004, 2: e355-PubMedCentralCrossRefPubMed
45.
Settle SH, Rountree RB, Sinha A, Thacker A, Higgins K, Kingsley DM: Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse Gdf6 and Gdf5 genes. Dev Biol. 2003, 254: 116-130.CrossRefPubMed
46.
Koyama E, Shibukawa Y, Nagayama M, Sugito H, Young B, Yuasa T, Okabe T, Ochiai T, Kamiya N, Rountree RB, Kingsley DM, Iwamoto M, Enomoto-Iwamoto M, Pacifici M: A distinct cohort of progenitor cells participates in synovial joint and articular cartilage formation during mouse limb skeletogenesis. Dev Biol. 2008, 316: 62-73.PubMedCentralCrossRefPubMed
47.
Mundy C, Yasuda T, Kinumatsu T, Yamaguchi Y, Iwamoto M, Enomoto-Iwamoto M, Koyama E, Pacifici M: Synovial joint formation requires local Ext1 expression and heparan sulfate production in developing mouse embryo limbs and spine. Dev Biol. 2011, 351: 70-81.PubMedCentralCrossRefPubMed
48.
49.
Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ: Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis. 2002, 33: 77-80.CrossRefPubMed
50.
Murao H, Yamamoto K, Matsuda S, Akiyama H: Periosteal cells are a major source of soft callus in bone fracture. J Bone Miner Metab. 2013, 31: 390-398.CrossRefPubMed
51.
Kawanami A, Matsushita T, Chan YY, Murakami S: Mice expressing GFP and CreER in osteochondro progenitor cells in the periosteum. Biochem Biophys Res Commun. 2009, 386: 477-482.PubMedCentralCrossRefPubMed
52.
Akiyama H, Kim JE, Nakashima K, Balmes G, Iwai N, Deng JM, Zhang Z, Martin JF, Behringer RR, Nakamura T, de Crombrugghe B: Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. Proc Natl Acad Sci U S A. 2005, 102: 14665-14670.CrossRefPubMed
53.
54.
55.
Grover J, Roughley PJ: Generation of a transgenic mouse in which Cre recombinase is expressed under control of the type II collagen promoter and doxycycline administration. Matrix Biol. 2006, 25: 158-165.CrossRefPubMed
56.
Branda CS, Dymecki SM: Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev Cell. 2004, 6: 7-28.CrossRefPubMed
57.
Chaiyachati BH, Kaundal RK, Zhao J, Wu J, Flavell R, Chi T: LoxP-FRT Trap (LOFT): a simple and flexible system for conventional and reversible gene targeting. BMC Biol. 2013, 10: 96-CrossRef
58.
Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L: Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A. 1994, 91: 9302-9306.PubMedCentralCrossRefPubMed
59.
Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H: Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996, 93: 10933-10938.PubMedCentralCrossRefPubMed
60.
Feil R, Wagner J, Metzger D, Chambon P: Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun. 1997, 237: 752-757.CrossRefPubMed
61.
Nakamura E, Nguyen MT, Mackem S: Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreER(T) to assay temporal activity windows along the proximodistal limb skeleton. Dev Dyn. 2006, 235: 2603-2612.CrossRefPubMed
62.
Chen M, Lichtler AC, Sheu TJ, Xie C, Zhang X, O'Keefe RJ, Chen D: Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. Genesis. 2007, 45: 44-50.PubMedCentralCrossRefPubMed
63.
Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D: Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 1999, 27: 4324-4327.PubMedCentralCrossRefPubMed
64.
Fosang AJ, Golub SB, East CJ, Rogerson FM: Abundant LacZ activity in the absence of Cre expression in the normal and inflamed synovium of adult Col2a1-Cre; ROSA26R(LacZ) reporter mice. Osteoarthritis Cartilage. 2013, 21: 401-404.CrossRefPubMed
65.
Jaenisch R, Mintz B: Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc Natl Acad Sci U S A. 1974, 71: 1250-1254.PubMedCentralCrossRefPubMed
66.
67.
68.
Ikawa M, Tanaka N, Kao WW, Verma IM: Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. Mol Ther. 2003, 8: 666-673.CrossRefPubMed
69.
Le Provost F, Lillico S, Passet B, Young R, Whitelaw B, Vilotte JL: Zinc finger nuclease technology heralds a new era in mammalian transgenesis. Trends Biotechnol. 2010, 28: 134-141.CrossRefPubMed
70.
Oumard A, Qiao J, Jostock T, Li J, Bode J: Recommended method for chromosome exploitation: RMCE-based cassette-exchange systems in animal cell biotechnology. Cytotechnology. 2006, 50: 93-108.PubMedCentralCrossRefPubMed
71.
Gordon J, Xiao S, Hughes B, Su DM, Navarre SP, Condie BG, Manley NR: Specific expression of lacZ and cre recombinase in fetal thymic epithelial cells by multiplex gene targeting at the Foxn1 locus. BMC Dev Biol. 2007, 7: 69-PubMedCentralCrossRefPubMed
72.
Weng T, Yi L, Huang J, Luo F, Wen X, Du X, Chen Q, Deng C, Chen D, Chen L: Genetic inhibition of fibroblast growth factor receptor 1 in knee cartilage attenuates the degeneration of articular cartilage in adult mice. Arthritis Rheum. 2012, 64: 3982-3992.PubMedCentralCrossRefPubMed
73.
Kohn A, Dong Y, Mirando AJ, Jesse AM, Honjo T, Zuscik MJ, O'Keefe RJ, Hilton MJ: Cartilage-specific RBPjkappa-dependent and -independent Notch signals regulate cartilage and bone development. Development. 2012, 139: 1198-1212.PubMedCentralCrossRefPubMed
74.
Blaney Davidson EN, Vitters EL, Bennink MB, van Lent PL, van Caam AP, Blom AB, van den Berg WB, van de Loo FA, van der Kraan PM: Inducible chondrocyte-specific overexpression of BMP2 in young mice results in severe aggravation of osteophyte formation in experimental OA without altering cartilage damage. Ann Rheum Dis. 2014, doi: 10.1136/annrheumdis-2013-204528
Metadata
Title
How to build an inducible cartilage-specific transgenic mouse
Authors
Esmeralda N Blaney Davidson
Fons AJ van de Loo
Wim B van den Berg
Peter M van der Kraan
Publication date
01-06-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4573

Other articles of this Issue 3/2014

Arthritis Research & Therapy 3/2014 Go to the issue

Research article

Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes

Commentary

Introduction: ‘Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?’

Letter

Response to ‘T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?’

Commentary

Why is there persistent disease despite biologic therapy? Importance of early intervention

Editorial

Moving towards personalized medicine in rheumatoid arthritis

Research article

Behçet’s disease in HLA-B*51 negative Germans and Turks shows association with HLA-Bw4-80I
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits